lorundrostat
lorundrostat: developed by 1 company · 2 clinical trials tracked.
lorundrostat evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could lorundrostat → MLYS affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Mineralys Therapeutics, Inc. (MLYS) Obstructive Sleep Apnea; Hypertension | Phase 2 |
Clinical Trials (2)
A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Crossover Study to Evaluate the Efficacy and Safety of Lorundrostat in Participants With Moderate to Severe Obstructive Sleep Apnea and Hypertension
Primary endpoint: Placebo-adjusted Change From Baseline in AHI at Week 4
An Open-Label Extension Study to Assess the Long-Term Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension
Primary endpoint: Change from MLS-101-301 baseline automated office blood pressure
Frequently asked questions
Who is developing lorundrostat?
lorundrostat is being developed by Mineralys Therapeutics, Inc..
How many clinical trials involve lorundrostat?
BioSniper tracks 2 clinical trials involving lorundrostat.